(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Gaza humanitarian efforts reach key milestone as UNICEF vaccinates some 13,000 children - 2Savvy Cleaning: The 6 Robot Vacuums of 2024
- 3Putting resources into Yourself: Self-awareness Techniques
- 4Sexual violence is being used as a weapon in Sudan's war, doctors group says
- 5Tech Patterns: Contraptions That Will Shape What's in store
- Manual for Tracking down One of a kind Store Inns
- German Winemakers Rewrite The Rules Of Riesling In A Warming World
- The most exciting exoplanet discoveries of 2025
- Posts falsely claim Netanyahu video fabricated to cover up his death
- Ancient fire discovery marks significant milestone in human history
- Interstellar comet 3I/ATLAS will fly by Earth Friday. Here are the latest images
- The most effective method to Consummate the Specialty of Handshaking in Business and Group environments
- PHOTO ESSAY: Scientists trying to unravel one of the body's biggest mysteries
- Lockheed Martin opens new hypersonic weapons facility
